Oral semaglutide: an innovative paradigm in the management of cardiovascular risk in patients with Type 2 diabetes.

Eur Heart J Suppl · 2025 · PMC11836705 · PMID 39980783

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

15 Furthermore, the meta-analyses of SUSTAIN (1–5) and PIONEER (1–5, 7–8) glycaemic efficacy studies, which included patients with Type 2 diabetes at relatively low CV risk, also showed a trend in 3p-MACE reduction (95% CI 0.55–1.33), suggesting a potential benefit in start semaglutide before clinical evidence of CVDs.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.